|
|
Guardant Health Inc (NASDAQ: GH) |
|
Price: $159.0200
$-2.48 
-1.536%
|
| Day's High:
| $162.13999938964844
| Week Perf:
| -3.58 %
|
| Day's Low: |
$ 155.63 |
30 Day Perf: |
-1.83 % |
| Volume (M): |
1,855,600 |
52 Wk High: |
$ 176.58 |
| Volume (M$): |
$ 0 |
52 Wk Avg: |
$106.43 |
| Open: |
$160.03 |
52 Wk Low: |
$53.40 |
|
|
| Market Capitalization (Millions $) |
20,875 |
| Shares
Outstanding (Millions) |
131 |
| Employees |
2,506 |
| Revenues (TTM) (Millions $) |
1,080 |
| Net Income (TTM) (Millions $) |
-433 |
| Cash Flow (TTM) (Millions $) |
298 |
| Capital Exp. (TTM) (Millions $) |
49 |
Business Description
Guardant Health Inc. is a leading precision oncology company that aims to transform cancer care through comprehensive genomic sequencing solutions. The company is based in Redwood City, California, and was founded in 2012 by Helmy Eltoukhy and AmirAli Talasaz.
Guardant Health's core technology is called Guardant360, a non-invasive liquid biopsy test that uses genomic sequencing to analyze a patient's cancer. This test allows oncologists to identify mutations and alterations in a patient's cancer DNA, which can help guide treatment decisions. In addition, Guardant Health has developed a range of other liquid biopsy tests, including GuardantOMNI, GuardantINFORM, and GuardantHEALTHY, which can detect cancer early, monitor disease progression, and identify potential relapse.
Guardant Health has also developed proprietary bioinformatics algorithms and machine learning techniques to interpret the large amounts of genomic data generated by these tests. These algorithms are used to predict a patient's response to various treatment options and identify new targets for therapeutics.
Guardant Health has partnerships with several global pharmaceutical companies to develop companion diagnostic tests for their cancer therapies. In addition, the company has formed collaborations with leading cancer centers and research institutions to conduct clinical trials and advance the use of liquid biopsies in cancer care.
In 2018, Guardant Health went public on the NASDAQ stock exchange, and its shares are now listed under the symbol GH. The company has rapidly grown its revenue and customer base, and in 2020, it was named one of the fastest-growing companies in North America by Deloitte's Technology Fast 500.
Guardant Health's mission is to help improve outcomes for cancer patients through precision oncology. The company is dedicated to using the power of genomics and data science to revolutionize cancer care and ultimately, find a cure for this devastating disease.
Company Address: 3100 Hanover Street Palo Alto 94304 CA
Company Phone Number: 698-8887 Stock Exchange / Ticker: NASDAQ GH
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Business Update
Published Fri, Dec 5 2025 8:11 PM UTC
Guardant Health Showcases Innovative Liquid Biopsy Research at SABCS Amid Strong Revenue Growth Guardant Health, Inc. (NASDAQ: GH), a prominent player in the precision oncology landscape, is set to present 14 abstracts at the upcoming 2025 San Antonio Breast Cancer Symposium (SABCS), scheduled for December 9-12, 2025. This presentation will highlight the contributions of its...
|
| Business Update
Published Thu, Nov 6 2025 8:34 AM UTC
PALO ALTO, Calif. In a landmark development for precision oncology, Guardant Health, Inc. (Nasdaq: GH) has announced groundbreaking findings related to its Shield blood test for colorectal cancer (CRC) screening. A recent real-world study published in Current Medical Research and Opinion indicates that the Shield test boasts a remarkable patient adherence rate of 95% amo...
|
| Business Update
Published Wed, Nov 5 2025 10:22 AM UTC
Guardant Health s Strategic Move: A $250 Million Public Offering to Fuel GrowthIn a significant move, Guardant Health, Inc., a trailblazer in precision oncology, has announced the commencement of an underwritten public offering aimed at raising $250 million through the sale of its common stock. The ambitious initiative, disclosed on October 25, 2023, reflects the companyâ€...
|
| Business Update
Published Mon, Jun 9 2025 4:27 PM UTC
In a significant breakthrough in the fight against early-stage breast cancer, Guardant Health, Inc. has announced promising results from its recent LIBERATE study, published in the esteemed journal ESMO Open. The study highlights the performance of Guardant Reveal, a minimal residual disease (MRD) blood test that employs advanced epigenomic (methylation) analysis to detect c...
|
| Business Update
Published Mon, Jun 2 2025 10:20 AM UTC
In a landmark achievement for the field of oncology, Guardant Health, Inc. (Nasdaq: GH), a trailblazer in precision oncology, has sparked significant progress in the detection and treatment of colon cancer through various strategic initiatives and groundbreaking research endeavors. In its latest stride, Guardant Health and its research collaborators have unveiled the results...
|
Fundamental Analysis
| Per Share |
Current |
| Earnings (TTM) |
-3.41 $ |
| Revenues (TTM) |
8.23 $
|
| Cash Flow (TTM) |
2.27 $ |
| Cash |
8.4 $
|
| Book Value |
-
|
| Dividend (TTM) |
0 $ |
| Efficiency
|
Current |
| Revenue per Employee
(TTM) |
431,051 |
| Net
Income per Employee (TTM) |
-172,862 |
| Receivable Turnover Ratio (TTM) |
8.29 |
| Inventory Turnover Ratio (TTM) |
4.41 |
| Asset Turnover Ratio (TTM) |
0.66 |
|
|
| Per Share |
|
| Earnings (TTM) |
-3.41 $
|
| Revenues (TTM) |
8.23 $ |
| Cash Flow (TTM) |
2.27 $ |
| Cash |
8.4 $
|
| Book Value |
- |
| Dividend (TTM) |
0 $ |
|
|
| |
| Oncology |
|
 67.94 % |
of total Revenue |
| Biopharma and data |
|
17.56 % |
of total Revenue |
| Screening |
|
13.79 % |
of total Revenue |
| Licensing and other |
|
0.71 % |
of total Revenue |
| Reportable Segment |
|
100 % |
of total Revenue |
| United States |
|
94.35 % |
of total Revenue |
| International |
|
5.65 % |
of total Revenue |
| |
On February 21 2025 the Guardant Health Inc provided following guidance
nnGuardant Health Inc. Offers Financial Insights and Projections for 2025nn
PALO ALTO, Calif. – Guardant Health, Inc. (Nasdaq: GH), a prominent player in the realm of precision oncology, has disclosed its financial outcomes for both the fourth quarter and the full year, which concluded on December 31, 2024.
### Fourth Quarter 2024 Financial Highlights:
For the three-month period ending December 31, 2024, the company demonstrated notable growth compared to the corresponding period in 2023. Here are the key figures:
- nnTotal Revenuenn: The company recorded an impressive total revenue of $201.8 million, reflecting a substantial increase of 30% year-over-year.
...
|
|
|
5.49% 